ライフサイエンスコーパス: oncolytic

1 uced pathogenicity in chickens but is highly oncolytic.

2 MV-Edm and is highly fusogenic and a potent oncolytic.

3 ial for the development of efficacious viral oncolytics.

4 ZIKV also displays therapeutic oncolytic activity against glioblastoma (GBM) stem cells

5 get cells expressing CD4 and retained robust oncolytic activity against HTLV-1 actuated ATL cells.

6 ndent therapeutic barrier and enhance oHSV-1 oncolytic activity in GBM.Significance: These findings s

7 antly, VSV-gp160G effectively exerted potent oncolytic activity in patient-derived ATL transplanted i

8 of HD5 in tumor cells diminished the in vivo oncolytic activity of mut-Ad3GFP but not of wt-Ad3GFP.

9 linical testing, infectivity and, therefore, oncolytic activity will not be compromised despite morph

10 suggest that infectivity (and, by inference, oncolytic activity) of rNDV virions is fully maintained

11 natural neurotoxicity while retaining potent oncolytic activity.

12 come the limitations in systemic delivery of oncolytic Ad (oAd) and to specifically target pancreatic

13 f oAd into hMSCs, a relaxin (RLX)-expressing oncolytic Ad (oAd/RLX), which degrades dense tumor extra

14 immune response against Ad. shMet-expressing oncolytic Ad (oAd; RdB/shMet) complexed with ABP-PEG-HCB

15 he RD Ad, proAdDelta24.GFP, into a fully RC, oncolytic Ad (rAdDelta24) that lyses tumor cells in cult

16 ate that gelatin gel-mediated co-delivery of oncolytic Ad and DCs might be a promising strategy to ef

17 tilized gelatin-based hydrogel to co-deliver oncolytic Ad co-expressing interleukin (IL)-12 and granu

18 icacy of the Ad/PEGbPHF complex platform, an oncolytic Ad expressing VEGF promoter-targeting transcri

19 sify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatmen

20 However, the systemic injection of oncolytic Ad in clinical applications is restricted due

21 ical trials have been done with either naked oncolytic Ad or combination with chemotherapies.

22 ioreducible polymer could be used to deliver oncolytic Ad safely and efficiently to treat hepatoma.

23 ation of dendritic cells (DCs) combined with oncolytic adenovirus (Ad) expressing antitumor cytokines

24 Oncolytic adenovirus (Ad) vectors present a promising mo

25 We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (n

26 Oncolytic adenovirus (oAd)-mediated gene therapy is a pr

27 used ECM-degrading and Wnt signal-disrupting oncolytic adenovirus (oAd/DCN/LRP) to achieve a desirabl

28 models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad

29 implications for clinical use of E3B-deleted oncolytic adenovirus and other E3B-deleted adenovirus ve

30 stify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the trea

31 our PeptiCRAd technology that consists of an oncolytic adenovirus coated with MHC-I-restricted tumor-

32 To test the hypothesis, we first constructed oncolytic adenovirus Delta-24-RGDOX expressing the immun

33 , we evaluated the mechanisms of LOAd713, an oncolytic adenovirus designed to block IL-6R signaling a

34 hours following in vitro infection with the oncolytic adenovirus dl922-947.

35 The oncolytic adenovirus ICOVIR-15K was engineered to expres

36 Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it h

37 Although oncolytic adenoviruses (Ads) are an attractive option fo

38 ach, allows for immediate screening of novel oncolytic adenoviruses and selection of optimal viral ge

39 ent a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments.

40 med tumor cells may provide insight into how oncolytic adenoviruses exploit metabolic transformation

41 have demonstrated good therapeutic index for oncolytic adenoviruses in patients with solid tumours wh

42 egulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improv

43 more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T

44 Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limita

45 Oncolytic adenoviruses, such as Delta-24-RGD (Delta24RGD

46 and has implications for cancer therapy with oncolytic adenoviruses.

47 clinical trials to assess its efficacy as an oncolytic agent against several cancers.

48 train of Newcastle disease virus (NDV) as an oncolytic agent for cancer therapy has been hampered by

49 yxovirus type 1, NDV, has been an attractive oncolytic agent for cancer virotherapy.

50 atitis virus (VSV) has promise as a systemic oncolytic agent for human cancer therapy.

51 sential step toward moving NDV forward as an oncolytic agent.

52 is being evaluated in clinical trials as an oncolytic agent.

53 extensively studied as a vaccine vector and oncolytic agent.

54 was aimed at testing the efficacy of IAVs as oncolytic agents for killing human PDA cell lines.

55 practical tool for local delivery of active oncolytic agents to tumor sites.

56 ates have a proven record as clinically used oncolytic agents.

57 pen new avenues for the use of reoviruses as oncolytic agents.

58 second-generation parvoviruses with enhanced oncolytic and immunostimulatory activities and rational

59 and for applications as a safety switch for oncolytic and live vaccine viruses.

60 ince VSIV is used as a backbone for multiple oncolytic and vaccine strategies, understanding how ISGs

61 gen that is also used as a backbone for many oncolytic and vaccine strategies.

62 glucose and glutamine metabolism induced by oncolytic and wild-type adenoviruses in cancer cells, wh

63 better known as tools for gene delivery and oncolytic anticancer therapy.

64 s to selectively target microglial cells for oncolytic applications.

65 Clinical trials of oncolytic attenuated measles virus (MV) are ongoing, but

66 what viral signature(s) constitutes a potent oncolytic backbone.

67 s establish a novel technology that enhances oncolytic cancer immunotherapy by capitalizing on pre-ac

68 er cells with wild-type adenoviruses and the oncolytic chimeric adenovirus enadenotucirev (EnAd).

69 on of VSV-LASV-GPC as a safe and efficacious oncolytic chimeric virus within the brain.

70 -24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited agains

71 However, the oncolytic effects differ, ranging from pronounced to lit

72 tion of these agents (CAd-VECPDL1) exhibited oncolytic effects with production of PD-L1 mini-body loc

73 data indicate that VSV-gp160G exerts potent oncolytic efficacy against CD4(+) malignant cells and ei

74 HD5 expression in cancer cells decreases the oncolytic efficacy of a serotype 5-based adenovirus vect

75 lasms of the CNS, such as immunotherapy with oncolytic engineered herpes simplex virus (HSV) therapy,

76 the family Poxviridae and possess promising oncolytic features.

77 fection and spread of replication-competent, oncolytic HAdV type 3 (HAdV3).

78 Oncolytic herpes simplex virus (oHSV) selectively replic

79 Oncolytic viruses, including oncolytic herpes simplex virus (oHSV), have produced pro

80 nt mice, and tested the fate and efficacy of oncolytic herpes simplex virus (oHSV)-armed mesenchymal

81 Oncolytic herpes simplex virus 1 (HSV-1), devoid of the

82 f viral growth within tumor cells.IMPORTANCE Oncolytic herpes simplex virus 1 is a promising agent fo

83 IRF3 solely in stromal fibroblasts restores oncolytic herpes simplex virus function.

84 Oncolytic herpes simplex virus G47Delta, which carried t

85 means substantially increased replication of oncolytic herpes simplex virus type 1 (oHSV).

86 Herein we demonstrate that oncolytic herpes simplex virus-1 (HSV-1) potently activa

87 ) but not 76-9 (MHC I low) tumors respond to oncolytic herpes simplex virus-1 (oHSV-1) and PD-1 block

88 Food and Drug Administration approval of the oncolytic herpesvirus talimogene laherparepvec in advanc

89 more efficient infection and replication by oncolytic HSV (oHSV).

90 r the development of more effective targeted oncolytic HSV vectors.

91 g the tumor-specific spreading of retargeted oncolytic HSV vectors.

92 on or deletion mutations and to construct an oncolytic HSV-1 that utilizes the disialoganglioside GD2

93 ead compound for further evaluation as novel oncolytic immunotherapeutic.

94 Oncolytic immunotherapies represent a new promising stra

95 EC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicat

96 e virus (NDV) is an attractive candidate for oncolytic immunotherapy due to its ability to replicate

97 roviding a potent, individual tumor-specific oncolytic immunotherapy for cancer patients, especially

98 T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benef

99 Oncolytic immunotherapy with PVSRIPO, the type 1 live-at

100 nd immune cells leads to tumor resistance to oncolytic immunotherapy.

101 uggest that PDOP is a promising platform for oncolytic immunotherapy.

102 loited for the development of improved viral oncolytics.IMPORTANCE TNBC is unresponsive to hormone th

103 immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry an

104 We studied a modified oncolytic myxoma virus (MYXV) that shows high efficiency

105 and T cells in the clearance and efficacy of oncolytic MYXV from gliomas.

106 genetics, we have generated a lead candidate oncolytic NDV based on the mesogenic NDV-73T strain that

107 tion and characterization of a highly potent oncolytic NDV variant that is unlikely to cause Newcastl

108 served in several paramyxoviruses.IMPORTANCE Oncolytic Newcastle disease virus (NDV) could establish

109 dronized polymer augments the efficacy of an oncolytic peptide (OP; KKWWKKWDipK) for immunotherapy by

110 Oncolytic peptides represent a promising new strategy wi

111 In our efforts to develop oncolytic peptides, we identified a series of chemically

112 Seneca Valley virus (SVV) is an oncolytic picornavirus with selective tropism for neuroe

113 ma model in vivo Our work reveals a distinct oncolytic platform that is amendable for further develop

114 rus could be eliminated without blocking its oncolytic potential in the brain by replacing the neurot

115 Here we hypothesized that an oncolytic poxvirus would attract T cells into the tumour

116 t lyses tumor cells in culture and generates oncolytic progeny virions.

117 tion of ICOVIR-15K-cBiTE, which retained its oncolytic properties in vitro cBiTE expression and secre

118 We map the enhanced oncolytic properties of r2Reovirus in TNBC to epistatic

119 We also map the enhanced oncolytic properties of r2Reovirus in TNBC to interactio

120 nd to limit both the immune presentation and oncolytic properties of these vectors.

121 oyed to improve the anticancer activities of oncolytic PVs, including development of second-generatio

122 on can be applied to switch RD Ad into fully oncolytic RC Ad for tumor therapy and is potentially app

123 We previously engineered an oncolytic reovirus (r2Reovirus) with enhanced infective

124 at a combination of a genetically engineered oncolytic reovirus and topoisomerase inhibitors may prov

125 The infectivity of oncolytic rNDV was found to be independent of ionic stre

126 l tropism for CD46 which is the basis of its oncolytic specificity.

127 ion but that could be "switched" into an RC, oncolytic state when needed might represent an advance i

128 ll as the application of measles virus as an oncolytic therapeutic.

129 They are also being developed as oncolytic therapeutics and as gene therapy vectors.

130 gies and improvement of lytic-phase-directed oncolytic therapies, therefore, hinge on gaining a bette

131 sidered vectors for recombinant vaccines and oncolytic therapies.

132 t leads on devising methods to improve viral oncolytic therapies.

133 s viral persistence and the effectiveness of oncolytic therapy for EBV(+) cancers.

134 in EBV biology and guide efforts to improve oncolytic therapy for EBV-associated cancers.

135 -Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a substantial fract

136 inducers of the lytic cycle are desired for oncolytic therapy.

137 er, these effects were further enhanced when oncolytic treatment was combined with immunogenic chemot

138 tential therapeutic target for antiviral and oncolytic treatments.

139 a therapeutic approach combining ACT with an oncolytic vaccine that allows simultaneous analysis of a

140 mor infiltration of the transferred T cells, oncolytic vaccines boosted tumor-primed host T cells.

141 ture and inhibits intravenously administered oncolytic vaccinia delivery to and consequent spread wit

142 of resistance to immunotherapies, including oncolytic vaccinia virotherapy.

143 efficacy of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive varia

144 e in colon and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and i

145 anslational Medicine, Park et al. develop an oncolytic vaccinia virus that introduces truncated CD19

146 We show here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment

147 nfiltrate of aggressive melanomas induced by oncolytic Vaccinia virus using RNA sequencing and found

148 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce

149 rapeutic efficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodi

150 ized features of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplifie

151 w targets both for antiviral therapy and for oncolytic vector design.IMPORTANCE This work is the firs

152 Oncolytic vectors engineered to express checkpoint block

153 r to conventional attenuated HSV vaccine and oncolytic vectors without sacrificing safety.

154 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancr

155 re sensitive and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

156 IFN-alpha2a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

157 Oncolytic viral (OV) therapy, which uses genetically eng

158 Oncolytic viral therapy and photodynamic therapy are pot

159 The basis for oncolytic viral therapy is the selective replication of

160 the first in-vitro study to combine reovirus oncolytic viral therapy with PpIX-mediated photodynamic

161 ation vaccine programs and as a safeguard in oncolytic viral therapy.

162 hogenesis and foster engineering of improved oncolytic viral vectors.

163 , a Leporipoxvirus, is being developed as an oncolytic virotherapeutic for the treatment of a variety

164 have supported the growing appreciation that oncolytic virotherapies primarily act as immunotherapies

165 Oncolytic virotherapy (OVT) is a promising approach in w

166 nvestigated as candidates for human systemic oncolytic virotherapy and gene therapy applications.

167 ibes poxviruses that are being developed for oncolytic virotherapy and summarizes the outcomes of bot

168 vestigated as a candidate for human systemic oncolytic virotherapy applications.

169 The first oncolytic virotherapy employing HSV-1 (oHSV-1) was appro

170 Oncolytic virotherapy exploits live viruses with selecti

171 Oncolytic virotherapy has been proposed as an ablative a

172 Both anti-PD1/PD-L1 therapy and oncolytic virotherapy have demonstrated promise, yet hav

173 ategy to enhance the therapeutic efficacy of oncolytic virotherapy in glioblastoma.

174 how to safely improve the efficacy of local oncolytic virotherapy in patients whose tumors are chara

175 Oncolytic virotherapy is an effective immunotherapeutic

176 Oncolytic virotherapy is an emerging therapeutic for the

177 emonstrating superior efficacy when poxvirus oncolytic virotherapy is combined with conventional ther

178 Oncolytic virotherapy is emerging as a solid therapeutic

179 These findings suggest that oncolytic virotherapy may improve the efficacy of anti-P

180 Oncolytic virotherapy of cancer can greatly benefit from

181 Oncolytic virotherapy represents an attractive option fo

182 The key role of type 1 IFN pathway in oncolytic virotherapy was also highlighted, as we observ

183 The use of orthoreoviruses for oncolytic virotherapy was critically assessed.

184 hase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on c

185 rrest, and it has important implications for oncolytic virotherapy, suggesting that frequent cell cyc

186 es with BiTE can overcome key limitations in oncolytic virotherapy.

187 ay can significantly improve outcomes during oncolytic virotherapy.

188 n pathogen but also as a promising agent for oncolytic virotherapy.

189 safety as well as the therapeutic outcome of oncolytic virotherapy.

190 indispensable for realizing the potential of oncolytic virotherapy.

191 umor cells, cardiac viral gene transfer, and oncolytic virotherapy.

192 (BiKEs and TriKEs), checkpoint blockade, and oncolytic virotherapy.

193 Drug Administration approval of immunogenic oncolytic virus (OV) has opened a new era in the treatme

194 Farrar et al demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein

195 Oncolytic virus (OV) therapy has emerged as a novel tool

196 ng VSV attachment and replication.IMPORTANCE Oncolytic virus (OV) therapy is an anticancer approach t

197 and cancer cells leads to enhanced growth of oncolytic virus (OV)-based therapeutics.

198 icular stomatitis virus (VSV) is a promising oncolytic virus (OV).

199 s being developed presently as a therapeutic oncolytic virus [talimogene laherparepvec (T-VEC)].

200 ation that could be used in both vaccine and oncolytic virus applications.

201 tacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the

202 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of can

203 nt tumor cell killing makes it an attractive oncolytic virus candidate that may provide clinical bene

204 an alternative region of dosing space (lower oncolytic virus dose, higher dendritic cell dose) for wh

205 -FH has significant advantages over MV as an oncolytic virus due to its higher viral yield, faster re

206 t that intratumoral immunomodulation with an oncolytic virus expressing a rationally selected ligand

207 ccines against infectious diseases and as an oncolytic virus for cancer therapy.

208 um iodide symporter (NIS) (VSV-mIFNbeta-NIS) oncolytic virus has significant antileukemia activity, w

209 ORF in the locus deleted in the FDA-approved oncolytic virus Imlygic.

210 In summary, this engineered oncolytic virus is able to activate tumor neoantigen-spe

211 We find that the oncolytic virus is able to secrete the PD-L1 inhibitor t

212 VSV is one oncolytic virus out of an arsenal of potential candidate

213 rtantly, the intratumoral injection with the oncolytic virus overcomes PD-L1-mediated immunosuppressi

214 Implications for the initial dynamics of oncolytic virus spread through tumors are discussed.

215 Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thu

216 In this study, we generate an engineered oncolytic virus that coexpresses a PD-L1 inhibitor and G

217 We explored the use of oncolytic virus therapy against glioblastoma with Zika v

218 f a safe and effective live-virus vector for oncolytic virus therapy and vaccines against smallpox, o

219 Oncolytic virus therapy is being evaluated in clinical t

220 A major challenge to oncolytic virus therapy is that individual cancers vary

221 randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor.

222 human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus au

223 s, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells.

224 inistering a single dose of TGFbeta prior to oncolytic virus treatment of glioblastoma can transientl

225 In this study, we combined ACT with oncolytic virus vaccines (OVVs) to drive expansion and t

226 e enhanced functional studies, generation of oncolytic virus vectors, development of delivery platfor

227 e cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on

228 Our data demonstrate that combining an oncolytic virus with tumor-targeting immune checkpoint m

229 icacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytot

230 RI) system to direct macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic

231 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and t

232 s aimed at promoting the optimum efficacy of oncolytic virus-based anticancer immunotherapies.

233 ating older approaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

234 e promise both as a vaccine vector and as an oncolytic virus.

235 ll positioned for clinical development as an oncolytic virus.

236 Oncolytic viruses (OV) preferentially kill cancer cells

237 Oncolytic viruses (OV) such as reovirus preferentially i

238 wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potentia

239 Oncolytic viruses (OVs) are emerging as important agents

240 In the last two decades, different oncolytic viruses (OVs) have been modified and tested in

241 The mode of action for oncolytic viruses (OVs) in cancer treatment is thought t

242 he critical question of how MSCs loaded with oncolytic viruses affect virotherapy outcomes and tumor

243 vides a new rationale for the combination of oncolytic viruses and chemotherapy.

244 subject to treatment with immunostimulatory oncolytic viruses and dendritic cell vaccines.

245 e we test whether the inflammatory nature of oncolytic viruses and their ability to remodel the tumor

246 n comparison with other clinically evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment s

247 Oncolytic viruses are an active area of clinical researc

248 tained in their pleomorphic forms.IMPORTANCE Oncolytic viruses are being developed for cancer therapy

249 Mesenchymal stem cells (MSCs) loaded with oncolytic viruses are presently being investigated as a

250 TANCE Vesicular stomatitis virus (VSV)-based oncolytic viruses are promising agents against pancreati

251 Vesicular stomatitis virus (VSV) based oncolytic viruses are promising agents against various c

252 oregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immun

253 Oncolytic viruses designed to attack malignant cells can

254 Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatm

255 them an advantage over interferon-sensitive oncolytic viruses in tumors showing residual interferon

256 show that MSC-mediated systemic delivery of oncolytic viruses is a promising strategy for achieving

257 The cancer-selective nature of some oncolytic viruses is based on the impaired innate immuni

258 ting of tumor cells by replication-competent oncolytic viruses is considered indispensable for realiz

259 l environment and the genetic composition of oncolytic viruses is crucial for the development of effi

260 Yet off-target infections by oncolytic viruses may increase virus production, further

261 Oncolytic viruses offer an in situ vaccination approach

262 Oncolytic viruses offer the attractive therapeutic combi

263 Oncolytic viruses pose many questions in their use in ca

264 ide metabolic support to tumor immunity, and oncolytic viruses represent a platform to deliver metabo

265 As such, oncolytic viruses represent a promising cancer-specific

266 Oncolytic viruses selectively lyse tumor cells, disrupt

267 Oncolytic viruses such as vesicular stomatitis virus (VS

268 the state of current research on the use of oncolytic viruses targeted to stem cells as a potential

269 of new therapeutic genes into the genome of oncolytic viruses that could not have been tested otherw

270 Engineering oncolytic viruses to express leptin in tumor cells induc

271 adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new

272 method to overcome this challenge is to use oncolytic viruses to induce secondary antitumor immune r

273 horses' to improve the delivery of drugs and oncolytic viruses to intractable tumours and are also be

274 into the interaction between CAR T cells and oncolytic viruses to optimize combination therapy.

275 However, responses to oncolytic viruses were incomplete due to metabolic insuf

276 ons may allow for the generation of modified oncolytic viruses with greater selective tumor cell repl

277 mathematical framework for assessing whether oncolytic viruses with reduced tumor-specificity can mor

278 to many therapies, including the efficacy of oncolytic viruses(2); however, the role of CAFs in this

279 on-competent viruses that kill cancer cells (oncolytic viruses).

280 ts and ultimately undermines the efficacy of oncolytic viruses, both in vitro and in vivo.

281 Checkpoint inhibitors, oncolytic viruses, cell-based immunotherapies, cytokines

282 infiltration of the tumor with immune cells, oncolytic viruses, drugs, and other therapeutics.

283 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

284 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

285 Oncolytic viruses, including oncolytic herpes simplex vi

286 Recently, however, many oncolytic viruses, including reovirus, have been reporte

287 ancer stemlike cells, cell cycle regulation, oncolytic viruses, new radiotherapy techniques, and immu

288 Unlike many other oncolytic viruses, we found no evidence that impairment

289 Oncolytic viruses, which replicate in cancer cells, indu

290 he rationale behind combination therapy with oncolytic viruses.

291 m other viruses show promise as vaccines and oncolytic viruses.

292 ividual cancers vary in their sensitivity to oncolytic viruses.

293 ssive mechanisms induced by MSCs loaded with oncolytic viruses.

294 great deal of progress in the development of oncolytic viruses.

295 to consider in the preclinical evaluation of oncolytic viruses.

296 and support further clinical development of oncolytic VSV recombinants as safe therapeutics for canc

297 n approach with our two previously described oncolytic VSV recombinants, VSV-p53wt and VSV-p53-CC, we

298 with IFN-alpha2a may enhance selectivity of oncolytic VSV therapy for HNSCC by inhibiting VSV replic

299 VSV-p53wt and VSV-p53-CC, we generated novel oncolytic VSVs with an improved ability to replicate in

300 viral evolution approach, we generated novel oncolytic VSVs with an improved ability to replicate in